3-methylsulfonyl-4-trifluoromethoxyphenyl isocyanate | 307990-41-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methylsulfonyl-4-trifluoromethoxyphenyl isocyanate
• 英文别名: 4-isocyanato-2-methylsulfonyl-1-(trifluoromethoxy)benzene
• CAS: 307990-41-6
• 化学式: C₉H₆F₃NO₄S
• 分子量: 281.212
• InChiKey: GPFKGRJQKJFFFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  81.2
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-[(4-Cyclohex-1-enylphenylamino)methyl]benzoic acid methyl ester 、 3-methylsulfonyl-4-trifluoromethoxyphenyl isocyanate 以 二氯甲烷 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Novel Glucagon Receptor Antagonists with Improved Selectivity over the Glucose-Dependent Insulinotropic Polypeptide Receptor

  摘要：

  Optimization of a new series of small molecule human glucagon receptor (hGluR) antagonists is described. In the process of optimizing glucagon receptor antagonists, we counter-screened against the closeli related human gastric inhibitory polypeptide receptor (hGIPR), and through structure activity analysis, we obtained compounds with low nanomolar affinities toward the hGluR, which were selective against the hGIPR and the human glucagon-like peptide-1 receptor (hGLP-1R). In the best cases, we obtained a >50 fold selectivity for the hGluR over the hGIPR and a > 1000 fold selectivity over the hGLP-1R. A potent and selective glucagon receptor antagonist was demonstrated to inhibit glucagon-induced glycogenolysis in primary rat hepatocytes as well as to lower glucagon-induced hyperolycemia in Sprague-Dawley rats. Furthermore. the compound was shown to lower blood glucose in the ob/ob mouse after oral dosing.

  DOI：

  10.1021/jm7015599
• 作为产物：
  描述：

  3-methylsulfonyl-4-trifluoromethoxyaniline 、 氯甲酸三氯甲酯 在 盐酸 作用下， 以 乙酸乙酯 、 甲苯 为溶剂， 生成 3-methylsulfonyl-4-trifluoromethoxyphenyl isocyanate
  参考文献：
  名称：

  Glucagon antagonists/inverse agonists

  摘要：

  揭示了一类新的化合物，其化学式为（I），其中V、A、Y、Z、R1、E、X和D的定义如规范中所述。这些化合物作用于拮抗胰高血糖素激素对胰高血糖素受体的作用。由于这些化合物对胰高血糖素受体的拮抗作用，它们适用于治疗或预防由胰高血糖素介导的疾病和病症，如高血糖、1型糖尿病、2型糖尿病和肥胖症。

  公开号：

  US06503949B1

文献信息

• Diazabicyclic histamine-3 receptor antagonists
  申请人：Howard R. Harry

  公开号：US20050282811A1

  公开（公告）日：2005-12-22

  This invention is directed to compounds of the formula I and II as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I or II, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I or II as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I or II as described above.

  本发明涉及本文所定义的I和II式化合物，或其药学上可接受的盐；包含I或II式化合物的药物组合物；一种治疗可能通过拮抗组胺H3受体而治疗的紊乱或状况的方法，该方法包括向需要此类治疗的哺乳动物施用上述I或II式化合物；一种治疗抑郁症、情绪障碍、精神分裂症、焦虑障碍、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏性气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道的高低运动性和酸性分泌的疾病的方法，该方法包括向需要此类治疗的哺乳动物施用上述I或II式化合物。
• Glucagon Antagonists/Inverse Agonists
  申请人：Lau Jesper

  公开号：US20090143592A1

  公开（公告）日：2009-06-04

  A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

  一种新型化合物，可拮抗胰高血糖素对胰高血糖素受体的作用。由于这些化合物对胰高血糖素受体的拮抗作用，这些化合物可能适用于治疗和/或预防任何胰高血糖素介导的疾病和病症，如高血糖、1型糖尿病、2型糖尿病和肥胖症。
• GLUCAGON ANTAGONISTS/INVERSE AGONISTS
  申请人：NOVO NORDISK A/S

  公开号：EP1183229B1

  公开（公告）日：2005-10-26
• US6503949B1
  申请人：——

  公开号：US6503949B1

  公开（公告）日：2003-01-07
• US6562807B2
  申请人：——

  公开号：US6562807B2

  公开（公告）日：2003-05-13